329 related articles for article (PubMed ID: 29925662)
1. Reduced Susceptibility to VIRIP-Based HIV-1 Entry Inhibitors Has a High Genetic Barrier and Severe Fitness Costs.
Müller JA; Glöckle A; Gawanbacht A; Geyer M; Münch J; Kirchhoff F
J Virol; 2018 Sep; 92(17):. PubMed ID: 29925662
[TBL] [Abstract][Full Text] [Related]
2. Development of resistance to VIR-353 with cross-resistance to the natural HIV-1 entry virus inhibitory peptide (VIRIP).
Gonzalez E; Ballana E; Clotet B; Esté JA
AIDS; 2011 Aug; 25(13):1557-83. PubMed ID: 21572303
[TBL] [Abstract][Full Text] [Related]
3. Compensatory mutations rescue the virus replicative capacity of VIRIP-resistant HIV-1.
González-Ortega E; Ballana E; Badia R; Clotet B; Esté JA
Antiviral Res; 2011 Dec; 92(3):479-83. PubMed ID: 22027647
[TBL] [Abstract][Full Text] [Related]
4. Mutations That Increase the Stability of the Postfusion gp41 Conformation of the HIV-1 Envelope Glycoprotein Are Selected by both an X4 and R5 HIV-1 Virus To Escape Fusion Inhibitors Corresponding to Heptad Repeat 1 of gp41, but the gp120 Adaptive Mutations Differ between the Two Viruses.
Zhuang M; Vassell R; Yuan C; Keller PW; Ling H; Wang W; Weiss CD
J Virol; 2019 Jun; 93(11):. PubMed ID: 30894471
[TBL] [Abstract][Full Text] [Related]
5. Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide.
Münch J; Ständker L; Adermann K; Schulz A; Schindler M; Chinnadurai R; Pöhlmann S; Chaipan C; Biet T; Peters T; Meyer B; Wilhelm D; Lu H; Jing W; Jiang S; Forssmann WG; Kirchhoff F
Cell; 2007 Apr; 129(2):263-75. PubMed ID: 17448989
[TBL] [Abstract][Full Text] [Related]
6. A low-molecular-weight entry inhibitor of both CCR5- and CXCR4-tropic strains of human immunodeficiency virus type 1 targets a novel site on gp41.
Murray EJ; Leaman DP; Pawa N; Perkins H; Pickford C; Perros M; Zwick MB; Butler SL
J Virol; 2010 Jul; 84(14):7288-99. PubMed ID: 20427524
[TBL] [Abstract][Full Text] [Related]
7. A novel bispecific peptide HIV-1 fusion inhibitor targeting the N-terminal heptad repeat and fusion peptide domains in gp41.
Jiang X; Jia Q; Lu L; Yu F; Zheng J; Shi W; Cai L; Jiang S; Liu K
Amino Acids; 2016 Dec; 48(12):2867-2873. PubMed ID: 27631437
[TBL] [Abstract][Full Text] [Related]
8. An optimized MM/PBSA virtual screening approach applied to an HIV-1 gp41 fusion peptide inhibitor.
Venken T; Krnavek D; Münch J; Kirchhoff F; Henklein P; De Maeyer M; Voet A
Proteins; 2011 Nov; 79(11):3221-35. PubMed ID: 21989940
[TBL] [Abstract][Full Text] [Related]
9. Short-term monotherapy in HIV-infected patients with a virus entry inhibitor against the gp41 fusion peptide.
Forssmann WG; The YH; Stoll M; Adermann K; Albrecht U; Tillmann HC; Barlos K; Busmann A; Canales-Mayordomo A; Giménez-Gallego G; Hirsch J; Jiménez-Barbero J; Meyer-Olson D; Münch J; Pérez-Castells J; Ständker L; Kirchhoff F; Schmidt RE
Sci Transl Med; 2010 Dec; 2(63):63re3. PubMed ID: 21178138
[TBL] [Abstract][Full Text] [Related]
10. Enfuvirtide resistance mutations: impact on human immunodeficiency virus envelope function, entry inhibitor sensitivity, and virus neutralization.
Reeves JD; Lee FH; Miamidian JL; Jabara CB; Juntilla MM; Doms RW
J Virol; 2005 Apr; 79(8):4991-9. PubMed ID: 15795284
[TBL] [Abstract][Full Text] [Related]
11. A Membrane-Anchored Short-Peptide Fusion Inhibitor Fully Protects Target Cells from Infections of Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus.
Tang X; Jin H; Chen Y; Li L; Zhu Y; Chong H; He Y
J Virol; 2019 Nov; 93(22):. PubMed ID: 31462566
[TBL] [Abstract][Full Text] [Related]
12. Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry.
Westby M; Smith-Burchnell C; Mori J; Lewis M; Mosley M; Stockdale M; Dorr P; Ciaramella G; Perros M
J Virol; 2007 Mar; 81(5):2359-71. PubMed ID: 17182681
[TBL] [Abstract][Full Text] [Related]
13. HIV-1 anchor inhibitors and membrane fusion inhibitors target distinct but overlapping steps in virus entry.
Eggink D; Bontjer I; de Taeye SW; Langedijk JPM; Berkhout B; Sanders RW
J Biol Chem; 2019 Apr; 294(15):5736-5746. PubMed ID: 30696772
[TBL] [Abstract][Full Text] [Related]
14. The Polar Region of the HIV-1 Envelope Protein Determines Viral Fusion and Infectivity by Stabilizing the gp120-gp41 Association.
Lu W; Chen S; Yu J; Behrens R; Wiggins J; Sherer N; Liu SL; Xiong Y; Xiang SH; Wu L
J Virol; 2019 Apr; 93(7):. PubMed ID: 30651369
[TBL] [Abstract][Full Text] [Related]
15. Mutations of Glu560 within HIV-1 Envelope Glycoprotein N-terminal heptad repeat region contribute to resistance to peptide inhibitors of virus entry.
Yuan C; Wang JY; Zhao HJ; Li Y; Li D; Ling H; Zhuang M
Retrovirology; 2019 Dec; 16(1):36. PubMed ID: 31796053
[TBL] [Abstract][Full Text] [Related]
16. Molecular mechanism of HIV-1 resistance to sifuvirtide, a clinical trial-approved membrane fusion inhibitor.
Yu D; Ding X; Liu Z; Wu X; Zhu Y; Wei H; Chong H; Cui S; He Y
J Biol Chem; 2018 Aug; 293(33):12703-12718. PubMed ID: 29929981
[TBL] [Abstract][Full Text] [Related]
17. Reversible and efficient activation of HIV-1 cell entry by a tyrosine-sulfated peptide dissects endocytic entry and inhibitor mechanisms.
Platt EJ; Gomes MM; Kabat D
J Virol; 2014 Apr; 88(8):4304-18. PubMed ID: 24478426
[TBL] [Abstract][Full Text] [Related]
18. Characterization of HIV-1 entry inhibitors with broad activity against R5 and X4 viral strains.
Sironi F; Malnati M; Mongelli N; Cozzi P; Guzzo C; Ghezzi S; Martínez-Romero C; García-Sastre A; Lusso P; Jabes D; Biswas P
J Transl Med; 2015 Apr; 13():107. PubMed ID: 25888743
[TBL] [Abstract][Full Text] [Related]
19. The C4 region as a target for HIV entry inhibitors--NMR mapping of the interacting segments of T20 and gp120.
Moseri A; Biron Z; Arshava B; Scherf T; Naider F; Anglister J
FEBS J; 2015 Dec; 282(24):4643-57. PubMed ID: 26432362
[TBL] [Abstract][Full Text] [Related]
20. Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics.
Reeves JD; Gallo SA; Ahmad N; Miamidian JL; Harvey PE; Sharron M; Pohlmann S; Sfakianos JN; Derdeyn CA; Blumenthal R; Hunter E; Doms RW
Proc Natl Acad Sci U S A; 2002 Dec; 99(25):16249-54. PubMed ID: 12444251
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
